<div>Our beautiful boy Jesse, now 4 years old, has been bravely fighting a rare childhood soft-tissue cancer called rhabdomyosarcoma since he was just 16 months old.
</div>
<div><br />
</div>
<div><strong>In July 2022, school had just broken up for summer holidays when we had to make a visit to A&amp;E as Jesse was complaining of abdominal pain. </strong>Doctors realised that Jesse was in urinary retention due to a large tumour in his pelvis (the size of an orange). We were quickly moved to Great Ormond Street Hospital where diagnosis was made and treatment began. We were told that although this cancer is extremely rare, outcomes with conventional treatment had around 70% survival rate.
</div>
<div><br />
</div>
<div><br />
</div><img alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/96219581_1765066369950270_r." width="100%" />
<div>(Through every round of treatment, Jesse has always kept his playful sense of humour)
</div>
<div><br />
</div>
<div>After his initial diagnosis, Jesse endured 6 weeks of intensive proton beam radiotherapy under daily general anaesthetic and 12 months of chemotherapy. His incredible strength and the care he received led to what we hoped would be a lasting recovery. For a time, we allowed ourselves to breathe again.
</div>
<div><br />
</div>
<div><strong>Unfortunately in Spring 2025 routine scans revealed that Jesse’s tumour had begun to rapidly grow again</strong>, and we were faced with limited treatment options through the NHS. We have been searching desperately for better options that could genuinely change his outcome. This has meant seeking a more personalised approach to Jesse's treatment as the standard treatment on offer has not changed for over 30 years and associated outcomes for relapsed disease have remained extremely poor.
</div>
<div><br />
</div>
<div><br />
</div><img alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/96219581_1765067256872412_r." width="100%" />
<div>(Keeping his spirits high through treatment)
</div>
<div><br />
</div>
<div><strong>December 2025</strong>
</div>
<div>Having undergone 4 rounds of the standard chemotherapy protocol which has only kept the tumour at bay, we now have a new and hopeful opportunity. <strong>Jesse has been offered specialised chemotherapy with adjuvant regional hyperthermia treatment in Germany</strong> — a highly targeted approach that research shows can be particularly effective for sarcoma. This treatment could significantly increase the chances of successful surgery and improve Jesse’s long-term prognosis. For the first time in a long time, we feel that there is a real possibility of some significant progress in gaining control of this disease.
</div>
<div><br />
</div>
<div><strong>This treatment is not available through the NHS, and we need to act quickly</strong>. At the moment we are aiming to raise enough to fund this treatment as well as a range of integrative therapies that keep Jesse strong and support him with the side effects of ongoing chemotherapy.
</div>
<div><br />
</div>
<ul>
<li>2 rounds of specialised chemotherapy/adjuvant hyperthermia and associated medical procedures and care in Germany including travel and accomodation - £30,000
</li>
<li>Personalised testing, consultancy and treatment planning - £5,000
</li>
<li>Integrative therapies - From vitamin supplements to high-dose IV therapy - £10,000
</li>
</ul>
<div><br />
</div>
<div>Even though this journey has been unbelievably hard, we are so grateful for the peace and strength that comes only from above. God has kept Jesse strong throughout and we remain full of hope. We are incredibly blessed to have the support and prayer of so many amazing friends and family on this journey and we genuinely feel we cannot do this without your help.
</div>
<div><br />
</div>
<div>Every donation, no matter the amount, brings Jesse closer to the treatment that could transform his future. Even sharing this page widely can have a powerful impact.
</div>
<div><br />
</div>
<div>Thank you, from the bottom of our hearts, for supporting Jesse and helping us reach the care that offers him his best chance.
</div>
<div><br />
</div>
<div>If you’d like to talk to us about Jesse’s condition or have any questions about his treatment, please get in touch - we’d love to hear from you.
</div>
<div><br />
</div>
<div>Simon, Anna, Jesse &amp; Jonah x
</div>
<div><br />
</div><img alt="" media_type="3" src="https://d2g8igdw686xgo.cloudfront.net/96219581_1765067968925750_r." width="100%" />
<div><br />
</div>
<div>Further reading on rhabdomyosarcoma and his treatment for those interested:
</div>
<div><br />
</div>
<div><a href="https://www.macmillan.org.uk/cancer-information-and-support/soft-tissue-sarcoma/rhabdomyosarcoma" target="_blank" rel="noreferrer noopener">What is Rhabdomyosarcoma?</a> (MacMillan)
</div>
<div>• Lancet Oncology (2010): Regional hyperthermia + chemotherapy improved survival in high-risk soft-tissue sarcoma.
</div>
<div><a href="https://pubmed.ncbi.nlm.nih.gov/20434400/" target="_blank" rel="noreferrer noopener"><a href="https://pubmed.ncbi.nlm.nih.gov/20434400/" target="_blank" class="" rel="nofollow noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/20434400/</a></a>
</div>
<div>• JAMA Oncology (2018): Long-term data confirming survival benefits of adding hyperthermia to chemotherapy in high-risk sarcoma.
</div>
<div><a href="https://pubmed.ncbi.nlm.nih.gov/29534015/" target="_blank" rel="noreferrer noopener"><a href="https://pubmed.ncbi.nlm.nih.gov/29534015/" target="_blank" class="" rel="nofollow noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/29534015/</a></a>
</div>
<div>• Cancers (2021): Feasibility + promising outcomes using hyperthermia with chemotherapy in paediatric sarcomas.
</div>
<div><a href="https://pubmed.ncbi.nlm.nih.gov/34830557/" target="_blank" rel="noreferrer noopener"><a href="https://pubmed.ncbi.nlm.nih.gov/34830557/" target="_blank" class="" rel="nofollow noopener noreferrer">https://pubmed.ncbi.nlm.nih.gov/34830557/</a></a>
</div>

Aoife Morgan

Kath Davies

Anonymous

Wally James

Sally Morris

ussef b

Lamine Hakki

Help Jesse Access Life-Changing Sarcoma Treatment

platform

Platform is iOS

Android

Adyen Google Pay Development Audience

$opt_dummy_attribute

English only

Deprecate Stripe Legacy

dyn_template_ids

Adyen V6 Bene Transfer & MyMoney Campaign Organizers - test01

Bene transfer V6 and AdyenV6MyMoney Campaign Organizers - production

OneTrust next-app audience

fundCountryCode

NextDoor Share Option Users

Fundraisers with Reactions feature capability

fundCurrencyCode

US + Non-charity COs Only

locale

fund country is US and user language is English

personId

comms-internal-person-ids

Enhanced Story Experience Users

Suggested Goal Experience Users

user language is English and fund country: US, AU, DK, FI, IE, NO, SE, CA, GB; 

Poster share - new funds eligible (newest 9/18)

Streaming widgets beta user

paymentProcessor

3DS payment method

user language is English and fundCountry: US, AU, DK, FI, IE, NO, SE, CA, GB; 

GoFundMe Employees

ipAddress

Mark Rieth IP Address

Version 9.2.0 and above

Fund is in English speaking country

desktop

Android v12.11.0 and above

Platform is Android

paymentMethodType

checkoutType

Payment method type group to be vaulted on success

admin pr kit prod

EUR Donation Upsell

Share Text generation Skip Fundraiser

(prod) new funds eligible for amp12 (UGC gallery)

fintrac_cad_idv_form_v2 audience

paymentProcessorAccountId

fallback mode accounts

proCampaignId

p2p legacy startfundraising page

AMP24 New Funds Only PROD (DO NOT MODIFY)

countryCode

charityId

UKCharities

Federated Search Internal Testing

route.pathname community

US Donation Upsell audience 

Auto Thanks Feature Audience

Supporter Comments Eligible Funds

International Only

fundId

braze fundraiser group 

Payment Identity Transfers ATO Risk Check (Targeted) - Production

Fundraiser Saved Payment Method Rate Limit Bypass (Production)

leaderboard-partner-id-audience-givepanel

Version 9.2.1 and above

AUD Donation Upsell audience

fundraiserCountryCode is US/EN

Active Fundraiser - Smart Default Cadence

DAF Internal

Vault on success card payment method

Platform is iOS v11.0.0 and above

Desktop users

Person ids

United States (US) users

allow yuno fundraisers for test

Mexico country code

Posters INTL

NPO Profile Opted-In

iOS at or above 12.4.0

non-US recurring donors

Canada Campaign Owner Group

Fundraiser Without Meta Link

Scheduler payment tester gorup

charityCommunityId

Charities allow to be claimed unclaimed (PRD)

Canada (CA) users

currencyCode

UC Tipping v20250115 International

pymk_production_xplr_fe_team

Android at or above 12.2.0

Profile photo entry point audience

smart goals (fundraiser/manage) on test01

Activity Tracking v1 Beta Testing

writePath

Stream Notification

start gfm intl allowed locales

Platform is iOS v11.2.0 and above

unclaimed charities

prod_ach_audience

AI Chatbot Audience

amp13 only new funds (prod) (anyword auto)

UC Flow Enabled (Prod)

Payment Identity Beneficiary Verification - Production

shared notification bell audience

Custom users

ach frontend audience

Android v11.0.0 and above

Users Receiving Payments Paused Notifications

smart goals test01

Manage Coach - US English Organizers Only + new funds only

Team EGG - IP Address list

Fundraiser Without Instagram Deep Link

Native 11.4.0 and above

UC Tipping v20250107

Users Receiving Braze KYC Validation Failed

Native 11.3.0 and above

Influencer - Prod

US fundraisers and US users

ai_title_page

anyword

openai

control

manual_entry

userEmail

template_id

userId

fundUrl

isCharityCo

email

appVersion

shouldBucketIntoExperiment

partnerId

donationCadence

isActiveFundraiser

isPartner

isMobile

npoProfileOptIn

fundIsLinkedWithMeta

hasSessionDonation

isCampaignOwner

fundHasInstagramDeepLink

Native 11.4.0 and higher

New funds eligible - Video Sharing (PROD)

GB Donation Upsell audience 

Auto Thanks V3 Rollout Audience

Thank you V3 testing whitelist

isRecurringFriendly

Is Recurring Friendly

Excluded funds - Video Sharing

Logged In Users

CH Donation Upsell audience

Android v10.6.0 and above

userCurrencyCode

Localized Currency

v11.5.0 and above

testAudience

pathname

Survicate

appVersion is at or above 12.8.0

Non-charity fund

isChallengeFundraiser

challenge-fundraisers

Payment Identity Launch Verification - Production

New funds eligible - Posters v2

CAD Donation Upsell Audience

Braze Email Tester

NPO Profile Opted-Out

iOS App Version

hasKnownDonors

PYMK has donors

iOS v12.3.0 and above

Help Jesse Access Life-Changing Sarcoma Treatment

Still £11,436 to go. Help us build momentum.